Sarepta Therapeutics, Inc.SRPTNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, below historical average, modest growth trend.
Left:
||||
Year-over-year operating income growth rate
Latest
-189.45%
↓ 352% below average
Average (39q)
75.18%
Historical baseline
Range
High:3266.33%
Low:-285.79%
CAGR
+5.4%
Consistent expansion
| Period | Value |
|---|---|
| Q3 2025 | -189.45% |
| Q2 2025 | 138.48% |
| Q1 2025 | -285.79% |
| Q4 2024 | 628.42% |
| Q3 2024 | 3266.33% |
| Q2 2024 | -102.01% |
| Q1 2024 | 41.75% |
| Q4 2023 | 218.15% |
| Q3 2023 | 84.39% |
| Q2 2023 | 3.31% |
| Q1 2023 | -29.26% |
| Q4 2022 | 18.67% |
| Q3 2022 | 37.79% |
| Q2 2022 | -143.01% |
| Q1 2022 | 17.89% |
| Q4 2021 | -207.08% |
| Q3 2021 | 79.44% |
| Q2 2021 | -10.34% |
| Q1 2021 | 11.04% |
| Q4 2020 | -24.55% |
| Q3 2020 | 0.93% |
| Q2 2020 | -17.22% |
| Q1 2020 | 48.73% |
| Q4 2019 | -86.28% |
| Q3 2019 | 55.12% |
| Q2 2019 | -260.49% |
| Q1 2019 | 45.19% |
| Q4 2018 | -98.81% |
| Q3 2018 | 32.22% |
| Q2 2018 | -236.47% |
| Q1 2018 | -32.80% |
| Q4 2017 | 49.58% |
| Q3 2017 | 27.52% |
| Q2 2017 | -61.39% |
| Q1 2017 | 55.60% |
| Q4 2016 | -56.36% |
| Q3 2016 | 8.96% |
| Q2 2016 | -4.02% |
| Q1 2016 | 7.37% |
| Q4 2015 | -24.51% |